A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Science Translational Medicine
Volume 14| Issue 628| 19 Jan 2022
https://www.science.org/toc/stm/current

 

Research Articles
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
BY William A. Fischer II, et al.
19 Jan 2022
Open Access
Molnupiravir (800-mg dose) accelerated SARS-CoV-2 RNA clearance in patients with COVID-19 compared to placebo.